Sort   by:  
 Page size 
UnknownPan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis.
Not available
S-EPMC9146019 | biostudies-literature
ProteomicsIntraductal xenografts reveal LOX inhibitor PXS-5505 as a translatable targeting strategy for lobular carcinoma exploiting a unique vulnerability
Fifteen percent of breast cancers are invasive lobular carcinomas (ILCs), a specific histological subtype. Although ILCs have distinct clinicopathological features and pathognomonic CDH1 loss, no specific therapies exist because ILCs are underrepresented in clinical trials and preclinical models are...
ORGANISM(S): Homo sapiens (Human) 
2026-01-29 | PXD065164 | Pride
Pxs-5505 Lobular carcinoma Lox inhibitor 
TranscriptomicsA First-in-Class Pan-Lysyl Oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer
The lysyl oxidase family represents a promising target in stromal targeting of solid tumours due to the importance of this family in cross-linking and stabilising fibrillar collagens, and its known role in tumour desmoplasia. Using small-molecule drug design approaches, we generated and validated PX...
ORGANISM(S): Mus musculus 
2023-05-18 | GSE186748 | GEO
UnknownLysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse.
Not available
S-EPMC8203624 | biostudies-literature
UnknownInhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies.
Not available
S-EPMC10023686 | biostudies-literature
UnknownA first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer.
Not available
S-EPMC10518255 | biostudies-literature
GenomicsSmall molecule inhibitors of LOXL synergize with 5-AZA to restore erythropoiesis in myeloid neoplasms
Objectives: Bone marrow (BM) stroma and microenvironmental factors in the BM milieu of myeloid neoplasms are increasingly being recognized as novel perspective therapeutic targets. Lysyl oxidases (LOX/LOXL) are crucial enzymes that cross-link collagen and contribute to the deposition of aberrant sti...
EGAS00001006174 | EGA
ProteomicsSmall molecule inhibitors of lysyl oxidases synergize with 5-azacytidine to restore erythropoiesis in myeloid neoplasms
In this study, we assessed the effects of lysyl oxidase (LOX/LOXL) inhibition on the composition of extracellular matrix (ECM) produced by in vitro expanded bone marrow derived mesenchymal stromal cells (MSCs) of n=3 patients with myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN...
ORGANISM(S): Homo sapiens (Human) 
2023-02-17 | PXD031217 | Pride
Msc Lc-ms Human Ecm 
GenomicsA First-in-Class Pan-Lysyl Oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer
A First-in-Class Pan-Lysyl Oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer
PRJNA775961 | ENA
Sort   by:  
 Page size